







an Open Access Journal by MDPI

# **Immunogenomics in Cancer**

Guest Editor:

#### Dr. Nikos G. Gavalas

Division of Clinical Therapeutics, National and Kapodistrian University of Athens, 157 72 Athens, Greece

Deadline for manuscript submissions:

25 September 2024

## **Message from the Guest Editor**

The immune system can recognize and attempt to reject cancer cells as foreign; however, cancer cells can develop ways to evade immune surveillance. Neoantigens, which are defined as highly cancer-specific proteins, generated from somatic mutations in individual patients, play pivotal roles in the development of anti-cancer immunity.

Immunogenomics stands at the forefront of today's research against cancer. The field itself combines immunology and genomics. More specifically, it includes the identification and analysis of genetic variations, mutations, and alterations in both cancer cells and the immune system.

Today, novel technologies and disciplines including next generation sequencing and computational biology allow for more effective study of immune response genetics against neoantigens and therapeutic regimes.

The aim of this Special Issue is to shed light on the genetics and genomics of the immune response against cancer. Novel research articles, letters, and review papers are welcome in order to form a collection of significant research items that promote the subject of immunogenomics in cancer.













an Open Access Journal by MDPI

## **Editor-in-Chief**

### Prof. Dr. Selvarangan Ponnazhagan

Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

## **Message from the Editor-in-Chief**

Genes are central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fastmoving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised.

Why not consider *Genes* for your next genetics paper?

#### **Author Benefits**

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

**Journal Rank:** JCR - Q2 (*Genetics & Heredity*) / CiteScore - Q2 (*Genetics*)

#### **Contact Us**